“Central Role For Industry Beckons As Europe Rebuilds After COVID” – Interview to Rebecca Guntern

Generics And Biosimilars Must Become A Central Policy Pillar, Says Rebecca Guntern

Generic and biosimilar medicines must become central to European healthcare policy as the region looks to rebuild in the wake of the COVID-19 pandemic, Medicines for Europe’s new president ad interim, Rebecca Guntern of Sandoz, tells Generics Bulletin in an exclusive interview.

Read more

Arun Narayan, Chairman of the Value Added Medicines Sector Group interviewed by the European Pharmaceutical review

The interview of Arun Narayan, Chairman ofthe Value Added Medicines Sector Group at Medicines for Europe, for the European Pharmaceutical Review on the importance of Value Added Medicines in achieving sustainable innovation, showing how existing molecules can offer various benefits for both patients & the healthcare sector when repurposed, reformulated, combined or paired with services or devices.

Open

EU Industry Welcomes New Schengen Strategy’s Green Lanes

“EU Industry Welcomes New Schengen Strategy’s Green Lanes”

Read more

Opinion piece by Christoph Stoller for Friends of Europe

“Too much at stake in the EU pharma strategy to get it wrong: how the EU can deliver equitable access to medicines”

Read more

EU Industry Welcomes New Schengen Strategy’s Green Lanes

“EU Industry Welcomes New Schengen Strategy’s Green Lanes”

Read more

Joint EU-UK pharmaceutical industry response to Specialised Committee outcome

Am fost foarte mândru de eforturile industriei noastre de a uni și a pune interesul pacienților absolut pe primul loc în timpul acestei crize

Interviu cu Adrian van den Hoven, director general Medicines for Europe 

Asociația Medicines for Europe, al cărui director general sunteți, a sesizat în perioada pandemiei o serie de probleme, întâlnite aproape în toate țările UE, anume disfuncționalități în asigurarea stocurilor de medicamente și proceduri greoaie de achiziții de produse și echipamente medicale. Care sunt propunerile dv. pentru rezolvarea acestora?

Readmore

IGBA: Global Roadmap for Tailored Clinical Biosimilar Development: Instrumental for Sustainable Access to Biologics

Joint press statement of European Pharmaceutical industry associations

Decisive action on medicines shortages should be included in pharmaceutical and industrial strategies